Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
THERIVA BIOLOGICS INC (TOVX) Stock Price & Overview
NYSEARCA:TOVX • US87164U5083
Current stock price
0.3586 USD
+0.03 (+8.67%)
At close:
0.3748 USD
+0.02 (+4.52%)
Pre-Market:
The current stock price of TOVX is 0.3586 USD. Today TOVX is up by 8.67%. In the past month the price increased by 58.25%. In the past year, price decreased by -74.01%.
TOVX Key Statistics
52-Week Range0.1628 - 1.465
Current TOVX stock price positioned within its 52-week range.
1-Month Range0.2153 - 0.492
Current TOVX stock price positioned within its 1-month range.
- Market Cap
- 16.456M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.86
- Dividend Yield
- N/A
TOVX Stock Performance
Today
+8.67%
1 Week
-5.88%
1 Month
+58.25%
3 Months
+99.22%
Longer-term
6 Months +14.79%
1 Year -74.01%
2 Years -96.44%
3 Years -97.72%
5 Years N/A
10 Years N/A
TOVX Stock Chart
TOVX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TOVX. When comparing the yearly performance of all stocks, TOVX turns out to be only a medium performer in the overall market: it outperformed 63.98% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TOVX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TOVX. TOVX may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TOVX Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.29
Revenue Reported
EPS Surprise 34.64%
Revenue Surprise %
TOVX Forecast & Estimates
8 analysts have analysed TOVX and the average price target is 2.55 USD. This implies a price increase of 611.1% is expected in the next year compared to the current price of 0.3586.
Analysts
Analysts82.5
Price Target2.55 (611.1%)
EPS Next Y92.87%
Revenue Next YearN/A
TOVX Financial Highlights
Over the last trailing twelve months TOVX reported a non-GAAP Earnings per Share(EPS) of -2.86. The EPS increased by 79.11% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-25.25M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.03% | ||
| ROE | -164.14% | ||
| Debt/Equity | 0.11 |
Chartmill High Growth Momentum
EPS Q2Q%91.21%
Sales Q2Q%N/A
EPS 1Y (TTM)79.11%
Revenue 1Y (TTM)N/A
TOVX Ownership
Ownership
Inst Owners2.86%
Shares45.89M
Float45.14M
Ins Owners0.02%
Short Float %5.64%
Short Ratio0.08
TOVX Industry Overview
TOVX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.4
- Average Fwd P/E
- 22.3
- Average Debt/Equity
- 2.2
TOVX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 373.774B | ||
| AMGN | AMGEN INC | 14.57 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.94 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 28.78 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.58 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.042B | ||
| INCY | INCYTE CORP | 10.43 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TOVX
Company Profile
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 15 full-time employees. The firm is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Company Info
IPO: 1993-02-12
THERIVA BIOLOGICS INC
9605 Medical Center Drive, Suite 270
Rockville MARYLAND US
Employees: 15
Phone: 17343327800
THERIVA BIOLOGICS INC / TOVX FAQ
What does THERIVA BIOLOGICS INC do?
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 15 full-time employees. The firm is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Can you provide the latest stock price for THERIVA BIOLOGICS INC?
The current stock price of TOVX is 0.3586 USD. The price increased by 8.67% in the last trading session.
What is the dividend status of THERIVA BIOLOGICS INC?
TOVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TOVX stock?
TOVX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does THERIVA BIOLOGICS INC belong to?
THERIVA BIOLOGICS INC (TOVX) operates in the Health Care sector and the Biotechnology industry.
Should I buy TOVX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TOVX.